DarioHealth Corp.

GRI Bio, Inc.

Supernus Pharmaceuticals, Inc.

Eikon Therapeutics, Inc.

Candel Therapeutics, Inc.

Compass Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Cartesian Therapeutics, Inc.

Annovis Bio, Inc.

Dilution score: 65/100 (HIGH), 7.9 months cash

13F fund flow: neutral, ? institutional managers

9 PubMed publications found for DarioHealth .

Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58.

Characterisation of digital therapeutic clinical trials: a systematic review with natural language processing.

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.

Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus.

Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

Short interest: 1.46% of float, squeeze risk: MODERATE

SW convergence: 50/100 (Neutral), 0 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="DRIO">
<p>DarioHealth Corp. (DRIO) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for DRIO were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001533998 (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22DRIO%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0001533998

DarioHealth Corp. (DRIO) — BioTechSigns Verified Summary

DarioHealth Corp. (DRIO) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for DRIO were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0001533998. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22DRIO%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17